Tharimmune, Inc. presented new clinical data for TH104 at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, which concluded on November 18, 2024. The data was derived from a Phase 1 trial of TH104 transmucosal buccal film in patients with chronic liver disease.
The presentation highlighted a significant correlation between TH104 blood levels and symptom relief, providing key insights into the drug's mechanism of action. The study also confirmed that TH104 was well tolerated, with no unexpected treatment-emergent adverse events observed.
These findings further support the development of TH104 for chronic pruritus in chronic liver disease. Preliminary data from the Phase 2 trial for chronic pruritus in primary biliary cholangitis is expected in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.